Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Study of Bocidelpar in Healthy Adults
NCT03682484Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Jun 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bocidelpar in Duchenne muscular dystrophy (DMD) and primary mitochondrial myopathy (PMM), sponsored by Astellas Pharma. Primary endpoints: Safety and tolerability assessed by nature, frequency, and severity of Adverse Events, Number of participants with vital sign abnormalities and 2 more. Started Jun 2017; status: completed.
02
Drugs
bocidelpar
03
Conditions
Duchenne muscular dystrophy (DMD)primary mitochondrial myopathy (PMM)
Beyond the preview
Go deeper on NCT03682484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03682484.